Please ensure Javascript is enabled for purposes of website accessibility

Why Acorda Therapeutics Shares Jumped

By Sean Williams - Apr 15, 2013 at 12:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive mid-stage results send Acorda shares to a new 52-week high.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Acorda Therapeutics (ACOR 1.45%), a commercial-stage biopharmaceutical company with a focus on central nervous system disorders, jumped as much as 13% after the company reported positive phase 2 trial data for experimental drug Ampyra for the treatment of post-stroke deficits.

So what: In mid-stage trials, 83 patients who had previously had an ischemic stroke within six months of enrollment and had other chronic motor deficits (in this case, a deficit would be considered impaired walking ability or impaired dexterity) were given Ampyra or the placebo twice daily for 14 days. The results demonstrated that Ampyra improved walking ability for those who had suffered an ischemic stroke. The data also showed that Ampyra provided patients with a positive improvement in functional independence over the placebo. Ampyra was well tolerated by those who took it, with predominantly minor side effects.

Now what: Now this looks like even more reason why Acorda Therapeutics should be on big pharma's buy list! I've been saying for more than a year now that Acorda would make a fantastic takeover target for a pharmaceutical company looking to bolster its CNS-line of medications. Acorda is profitable, has nearly $6 in net cash per share, and has six ongoing clinical trials. What more do you need from a biotechnology company?

Craving more input? Start by adding Acorda Therapeutics to your free and personalized Watchlist so you can keep up on the latest news with the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
$0.42 (1.45%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.